Slide 1: Fourth Quarter and Fiscal Year End 2020 Operating & Financial Results Conference Call
Fourth Quarter and Fiscal Year End 2020 Operating & Financial Results Conference Call https://ir.lanternpharma.com/ March 10, 2021 4 PM Eastern
Slide 2: Forward-Looking Statements
LTRN FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, stateme
Slide 3: Key Topics
KEY TOPICS 1. Business Overview & Background Panna Sharma, CEO 2. Financial Results & Highlights Fourth Quarter and David Margrave, CFO Fiscal Year End 2020 3. Business Updates Operating & Financial Panna Sharma, CEO Results Conference Call 4. Milestones Panna Sharma, CEO March 10, 2021 4 PM Eastern
Slide 4: Lantern leverages A.I. to rescue and develop cancer therapies
Lantern leverages A.I. to rescue and develop cancer therapies and has the potential to transform the cost, risk and timeline of drug development Failed or Abandoned Drug Assets Responders Non-Responders RADR® & New Drug Development • Big data (genomic, clinical, response) • Patient stratification ba
Slide 5: Lantern's Unique & Rapidly Developing Pipeline
Lantern’s Unique & Rapidly Developing Pipeline Accelerated Development by Leveraging the RADR® A.I. Platform 70+ issued patents and pending applications across 14 patent families 5
Slide 6: Milestones Attained Since June 2020 IPO
Milestones Attained Since June 2020 IPO Drug Development Achievements - Expanded pipeline from 3 drug candidates in 4 tumor targets to 7 disclosed targets - Initiated Antibody Drug Conjugate (“ADC”) platform - Grew RADR® A.I. platform to over 1.2 billion datapoints, ~5x from IPO - Published multiple
Slide 7: Summary Results of Operations
Summary Results of Operations Three Months Ended Year Ended December 31, December 31, (Unaudited) 2020 2019 2020 2019 Operating expenses: General and administrative 1,547,675 497,700 3,664,965 1,475,000 Research and development 1,348,329 177,468 2,243,225 953,185 Total operating expenses 2,896,004 6
Slide 8: Balance Sheet Highlights & Summary
Balance Sheet Highlights & Summary 12/31/2020 12/31/2019 Cash $ 19,229,232 $1,232,030 Prepaid Expenses & Other Current Assets $1,007,690 788 Total Assets $ 20,359,634 $ 1,432,576 Total Liabilities $ 660,839 $ 489,292 Total Stockholders’ Equity $ 19,698,795 $ 943,284 Cash position does not include $6
Slide 9: Follow-On Offering – January 20, 2021
Follow-On Offering – January 20, 2021 4,928,571 shares at $14.00 per share $68,999,994 Gross Proceeds LANTERN PHARMA INC. (LTRN) Common Shares Outstanding 11,169,665 Warrants 305,294 Options (Employees, Management and Directors) 835,608 Fully Diluted Shares Outstanding 12,310,567 9
Slide 10: Entering "The Golden Age of A.I."
Entering “The Golden Age of A.I.” 10 Mega-Trends Setting The Stage for A.I. Led Transformation in Drug Development & Medicine ✦ Large-scale, relevant and readily available data-sets ✦ Methods, technologies and algorithms that are massively scalable ✦ Computing, storage and transmission continue expo
Slide 11: The RADR Platform Enables...
The RADR® Platform Enables... ➢ Rapid identification of potential compounds to Data Points Powering RADR® rescue and develop Scientific Value + ➢ Improved and more nuanced understanding of responder groups, and non-responder groups based on biological networks ➢ Feedback for potential mechanisms to
Slide 12: RADR Platform Key Features & Architecture
RADR® Platform Key Features & Architecture 85%+ RADR® rapidly identifies genetic & 1 Blinded biomarker signatures for precision prediction success oncology drug development, 75,000+ clinical response prediction and Cancer patient CDx (companion diagnostic) clinical histories enablement. 144+ Drug-tu
Slide 13: Growth in Data Drives Growth in Capabilities
Growth in Data Drives Growth in Capabilities The Data Powering our AI Platform is on pace to grow ~120x since January 2019 (Data points expressed in millions) 3,000 • Complete transcriptome data • RNA gene expression data • Drug sensitivity data • DNA copy number and mutation data 1,500 • Clinical s
Slide 14: Biomarker Signature is Based on Statistical Significance and Biological Relevance
Biomarker Signature is Based on Statistical Significance and Biological Relevance RADR® automates machine-learning approaches in generating a biomarker based response signature that can be used throughout the lifecycle of therapy development: 1. Preclinical modeling and studies 2. Clarifying mechani
Slide 15: LP-184 Shows In Vitro Potency in ATRT Cancer
LP-184 Shows In Vitro Potency in ATRT Cancer LP-184 IC50 values in multiple ATRT cell lines - Ultra-rare CNS cancer mostly suggest ability to potently 1 kill these cancers occurring in children driven by 1770 SMARCB1 expression as 1000 predicted by RADR® LP-184 IC50 [nM] 162 - Additional validation
Slide 16: Collaboration Focused on Glioblastoma (GBM) for LP-184
Collaboration Focused on Glioblastoma (GBM) for LP-184 FOCUS: This Johns Hopkins collaboration is focused on establishing LP-184 as a superior agent in GBM, as well as qualifying LP-184 for an orphan drug designation in this rare tumor type. GOAL: The goal of the collaboration is to demonstrate the
Slide 17: Key Value Building Objectives
Key Value Building Objectives Foundational Year Multiple Streams of Value Creation Advance Platform Launch Multiple Precision Trials Prepare Trial Launches Leverage Platform for Pharma Partners Prioritize Additional Compounds Secure Additional Compounds 2021 2022 ● Planned launch of Ph. 2 clinical t
Slide 18: Upcoming Conference & Presentation Schedule
Upcoming Conference & Presentation Schedule 3/9-10/2021 H.C. Wainwright & Co. Global Life Sciences Conference Virtual Investor 3/24-25/2021 Benzinga Healthcare Conference Conferences 4/12-15/2021 Needham 20th Annual Healthcare Conference LTRN 5/4-5/2021 7th Annual Truist Securities 2021 Life Science
Slide 19: Q&A
Q&A LTRN Operating & Financial Results Call March 10, 2021 19